These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 2795602)

  • 1. Oral hypoglycemic agents. Discovery and structure-activity relationships of phenacylimidazolium halides.
    Dominianni SJ; Yen TT
    J Med Chem; 1989 Oct; 32(10):2301-6. PubMed ID: 2795602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sulfonyliminoimidazolidines. A new class of oral hypoglycemic agents. 2. Mode of action and X-ray structure of 1-[[p-[2-(crotonylamino)ethyl]phenyl]sulfonyl]-3-cyclohexyl-2-iminoimidazolidine.
    Schweizer EH; Märki F; Rihs G
    J Med Chem; 1983 Jul; 26(7):970-3. PubMed ID: 6345781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and cytotoxic activities of novel phenacylimidazolium bromides.
    Yang XD; Zeng XH; Zhang YL; Qing C; Song WJ; Li L; Zhang HB
    Bioorg Med Chem Lett; 2009 Apr; 19(7):1892-5. PubMed ID: 19269816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and synthesis of imidazoline derivatives active on glucose homeostasis in a rat model of type II diabetes. 2. Syntheses and biological activities of 1,4-dialkyl-, 1,4-dibenzyl, and 1-benzyl-4-alkyl-2-(4',5'-dihydro-1'H-imidazol-2'-yl)piperazines and isosteric analogues of imidazoline.
    Le Bihan G; Rondu F; Pelé-Tounian A; Wang X; Lidy S; Touboul E; Lamouri A; Dive G; Huet J; Pfeiffer B; Renard P; Guardiola-Lemaître B; Manéchez D; Pénicaud L; Ktorza A; Godfroid JJ
    J Med Chem; 1999 May; 42(9):1587-603. PubMed ID: 10229628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Substituted thiazolidinediones and thio-imidazolidinones: synthesis, structural study and pharmacological activity.
    Albuquerque JF; Albuquerque A; Azevedo CC; Thomasson F; Galdino LS; Chantegrel J; Catanho MT; Pitta IR; Luu-Duc C
    Pharmazie; 1995 Jun; 50(6):387-9. PubMed ID: 7651975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sulfonyliminoimidazolidines. A new class of oral hypoglycemic agents. 1. 1-[[p-[2-(acylamino)ethyl]phenyl]sulfonyl]-2-iminoimidazolidines.
    Schweizer EH; Märki F; Lehmann C; Dietrich H
    J Med Chem; 1983 Jul; 26(7):964-70. PubMed ID: 6864736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and hypoglycemic activity of 2-(omega-substituted alkylamine)-2-imidazolines.
    Reisner DB; Ludwig BJ; Gister S; Tomeczek K
    J Med Chem; 1970 Jan; 13(1):142-3. PubMed ID: 5412089
    [No Abstract]   [Full Text] [Related]  

  • 8. Compound M & B 39890A [N-(3-imidazol-1-ylpropyl)- 2-(3-trifluoromethylbenezensulphonamido)-benzamide hydrochloride], a glucagon and insulin secretion inhibitor, improves insulin sensitivity in viable yellow obese-diabetic mice.
    Yen TT; Schmiegel KK; Gold G; Williams GD; Dininger NB; Broderick CL; Gill AM
    Arch Int Pharmacodyn Ther; 1991; 310():162-74. PubMed ID: 1772327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and hypoglycemic activity of phenacyltriphenylphosphoranes and phosphonium salts.
    Blank B; DiTullio NW; Deviney L; Roberts JT; Saunders HL
    J Med Chem; 1975 Sep; 18(9):952-4. PubMed ID: 1159720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclization of lactamimide ketones to imidazo(1,2-a)-azacycloalkanes with hypoglycemic activity.
    Claxton GP; Grisar JM; Wiech NL
    J Med Chem; 1974 Mar; 17(3):364-7. PubMed ID: 4811238
    [No Abstract]   [Full Text] [Related]  

  • 11. Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus.
    Pfefferkorn JA; Guzman-Perez A; Litchfield J; Aiello R; Treadway JL; Pettersen J; Minich ML; Filipski KJ; Jones CS; Tu M; Aspnes G; Risley H; Bian J; Stevens BD; Bourassa P; D'Aquila T; Baker L; Barucci N; Robertson AS; Bourbonais F; Derksen DR; Macdougall M; Cabrera O; Chen J; Lapworth AL; Landro JA; Zavadoski WJ; Atkinson K; Haddish-Berhane N; Tan B; Yao L; Kosa RE; Varma MV; Feng B; Duignan DB; El-Kattan A; Murdande S; Liu S; Ammirati M; Knafels J; Dasilva-Jardine P; Sweet L; Liras S; Rolph TP
    J Med Chem; 2012 Feb; 55(3):1318-33. PubMed ID: 22196621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular design, synthesis, and hypoglycemic activity of a series of thiazolidine-2,4-diones.
    Oguchi M; Wada K; Honma H; Tanaka A; Kaneko T; Sakakibara S; Ohsumi J; Serizawa N; Fujiwara T; Horikoshi H; Fujita T
    J Med Chem; 2000 Aug; 43(16):3052-66. PubMed ID: 10956213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and synthesis of novel imidazoline derivatives with potent antihyperglycemic activity in a rat model of type 2 diabetes.
    Crane L; Anastassiadou M; El Hage S; Stigliani JL; Baziard-Mouysset G; Payard M; Leger JM; Bizot-Espiard JG; Ktorza A; Caignard DH; Renard P
    Bioorg Med Chem; 2006 Nov; 14(22):7419-33. PubMed ID: 16889967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoglycemic activity of curcumin synthetic analogues in alloxan-induced diabetic rats.
    Das KK; Razzaghi-Asl N; Tikare SN; Di Santo R; Costi R; Messore A; Pescatori L; Crucitti GC; Jargar JG; Dhundasi SA; Saso L
    J Enzyme Inhib Med Chem; 2016; 31(1):99-105. PubMed ID: 25683079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of a series of imidazo[4,5-b]pyridines with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ.
    Casimiro-Garcia A; Filzen GF; Flynn D; Bigge CF; Chen J; Davis JA; Dudley DA; Edmunds JJ; Esmaeil N; Geyer A; Heemstra RJ; Jalaie M; Ohren JF; Ostroski R; Ellis T; Schaum RP; Stoner C
    J Med Chem; 2011 Jun; 54(12):4219-33. PubMed ID: 21557540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of net hepatic substrate balance by phenacylimidazolium ions in the conscious dog.
    Pagliassotti MJ; Colburn CA; Moore MC; Neal DW; Dominianni SJ; Stephens TW; Cherrington AD
    Diabetes Res; 1993; 22(3):123-33. PubMed ID: 7915646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis of N-(3,6-dihydro-1(2H)-pyridinyl)benzamides with hyperglycemic-hypoglycemic activity.
    Yeung JM; Knaus EE
    J Med Chem; 1987 Jan; 30(1):104-8. PubMed ID: 3806586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral hypoglycemic agents. Pyrimido[1,2-a]indoles and related compounds.
    Cliffe IA; Lien EL; Mansell HL; Steiner KE; Todd RS; White AC; Black RM
    J Med Chem; 1992 Apr; 35(7):1169-75. PubMed ID: 1560431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Structure-activity relationships in reactivators of acetylcholinesterase inhibited by organophosphoric compounds. 8. Halides of 2- and 4-hydroxy-iminomethyl-1-(omega-(4-imidazolyl)-n-alkyl)pyridinium].
    Franchetti P; Grifantini M; Martelli S; Stein ML
    Farmaco Sci; 1974 Apr; 29(4):309-16. PubMed ID: 4857121
    [No Abstract]   [Full Text] [Related]  

  • 20. New potent antihyperglycemic agents in db/db mice: synthesis and structure-activity relationship studies of (4-substituted benzyl) (trifluoromethyl)pyrazoles and -pyrazolones.
    Kees KL; Fitzgerald JJ; Steiner KE; Mattes JF; Mihan B; Tosi T; Mondoro D; McCaleb ML
    J Med Chem; 1996 Sep; 39(20):3920-8. PubMed ID: 8831758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.